Jurisdictions: Setup alerts … Indicate the party certifying the report (select only one). ITEM 1 REPORT TYPE
(YYYY-MM-DD) ITEM 1 REPORT TYPE ft. genetics Lab still under construction. Jurisdictions: 4 Microsoft Word - 41091500_1 39249131_1|NATDOCS
Indicate the party certifying the report (select only one). Date: October 7, 2019 Any interested party should undertake their own inquiries as to the accuracy of the information. Indicate the party certifying the report (select only one).
Jurisdictions: Mark Swaenepoel Andrew Simpson, Vice President Vice President, +1 780 969 3037 +1 780 969 3001, Mark.firstname.lastname@example.org Andrew.email@example.com, Brief of Synergy for Receivership Application– May 12, 2020, Affidavit of Tim Varughese – May 12, 2020, Affidavit of Tim Varughese in opposition of application – May 15, 2020, Brief of Synergy in Response to opposition of application – May 15, 2020, Application by Receiver for Order Increasing Borrowing Power and Other Relief, Letter to Court Coordinator – August 4, 2020, Receivership Order – May 22, 2020 (2003 07758), Receivership Order – May 22, 2020 (2003 07757), Order Increasing Borrowing Power and Other Relief – August 17, 2020, Lien Claims Adjudication Order – August 17, 2020. As previously disclosed, on May 23, 2019, the Company was advised that it no longer complied with the minimum $2,500,000 stockholders' equity requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). Access to the Portfolio’s online due diligence data room is available to qualified parties upon execution of a confidentiality agreement. (YYYY-MM-DD) With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of obstructive sleep apnea (OSA), and for the treatment of pain; and THX-160 for the treatment of pain; and an additional drug development program based on non-psychoactive cannabinoid Cannabidiol (CBD) and palmitoylethanolamide (PEA) for the treatment of epilepsy, as well as inflammatory conditions. After reviewing the Company's plan to regain compliance, Nasdaq granted an extension to enable the Company to regain compliance with the Stockholders' Equity Requirement until November 18, 2019. Amended report If amended, provide filing date of report that is being amended. Investor Contact: Elizabeth Barker KCSA Strategic Communications +1-212-896-1203 [email protected], Cision Distribution 888-776-0942 Date: May 8, 2019 Date: August 2, 2019 The Company did not regain compliance with the Stockholders' Equity Rule as a result of abandoning the proposed merger with Destiny Bioscience … Cannabis Industrial Marketplace interconnects industrial and business buyers with industrial sellers, and does not promote or condone the use of Cannabis products. Amended report If amended, provide filing date of report that is being amended. Microsoft Word - 37872937_1 X New report Access and download the latest documents for Destiny Bioscience Global Corp. (previously, 1825159 Alberta Ltd.) Search within PDF documents. A hearing request by the Company automatically stays the delisting of the Company's securities pending issuance of the Panel's decision. Destiny Bioscience | 300 followers on LinkedIn.
X New report
The Downing FOUR VCT PLC Healthcare Technology Fund is managed by Downing LLP BioScience Managers Pty … 4
Amended report If amended, provide filing date of report that is being amended. PROPERTY 2: Leduc Micro Cultivation & Lab Building: 11,040 SF lease interest in a state-of-the-art cannabis cultivation and lab facility, 90% complete, planned for EUGMP certification, Designed for cannabis cultivation, extraction lab, genomics lab, and tissue propagation lab, State-of-the-art, cannabis specific mechanical systems installed, Attractive lease terms with 2 x 5 year renewal options.